PreciGenome

NanoGenerator® Instrument for Lipid Nanoparticle formulation and preparation. Power tool for mRNA-LNP drug delivery study. NanoGenerator Instrument for Lipid Nanoparticle formulation and preparation, mRNA-LNP drug delivery More information. https://lnkd.in/gUTwWPFP NanoGenerator® is a high-performance nanoparticles synthesis system for the formulating and preparing nanoparticles, including lipid nanoparticles LNP, liposomes, PLGA, etc. Lipid nanoparticle synthesis is the process of creating lipid nanoparticles, which are a type of drug delivery system that encapsulate therapeutic molecules in a lipid shell. LNP synthesis plays a crucial role in drug delivery and therapeutics. NanoGenerator synthesis system generates nanoparticles with better uniformity in size and smaller PDI. It is scalable from 0.1mL/sample screening up to 1L - 20L with custom design large volume GMP production. #lnp #drugdelivery #lipidnanoparticles #nanoparticles #drugdiscovery #mrna #formulation #cdmo #cro #pharmaceuticals #therapeutics

Happy new year！

Proud to be an active member of the Spoke 8 Team! 🎉 We've adopted the PreciGenome microfluidic system to formulate an innovative #mRNA targeting #platform. Excited to see where this cutting-edge technology takes us! Dipmed Unisa Università degli Studi di Salerno

Applications of Microfluidics in mRNA Vaccine Development: A Review Excited to share recent publication, "Applications of Microfluidics in mRNA Vaccine Development: A Review," authored by Ali Fardoost, Koosha Karimi, Harshitha Govindaraju, Pegah Jamali, and Mehdi Javanmard, published in Biomicrofluidics on November 14, 2024. *Microfluidic technologies enable precise and rapid formulation of lipid nanoparticles (LNPs) for mRNA delivery, improving vaccine efficacy and consistency. *The Nanogenerator from PreciGenome is highlighted for its pivotal role in controlling the size and encapsulation efficiency of LNPs, making mRNA vaccine production more scalable. Microfluidics offers a promising future for faster, more personalized, and cost-effective vaccine manufacturing. Check out the full paper here: https://lnkd.in/gJ4HzfN6 #AliFardoost #KooshaKarimi #MehdiJavanmard #HarshithaGovindaraju #PegahJamali #Nanogenerator #PreciGenome #mRNAvaccines #Microfluidics #drugdelivery

A glimpse into the fascinating world of creating lipid nanoparticles (LNPs), essential for drug delivery and mRNA vaccines. Stay connected to witness the groundbreaking work as we strive to revolutionize healthcare through cutting-edge nanoparticle research! hashtag #ScienceInnovation #MedicalBreakthroughs #LNPs #DrugDelivery

Excited to share a groundbreaking paper: "Microfluidic-Engineered PLA/PLGA Nanocarriers for Cellular Tracking" published in the International Journal of Pharmaceutics (January 2024). Key findings from our research team: • Successfully developed uniform PLA/PLGA nanocarriers with precise size control (PreciGenome Nanogenerator Flex system) • Demonstrated efficient cellular uptake and distribution tracking using both fluorescent and gold-loaded carriers This work opens new possibilities for targeted drug delivery and cellular tracking applications! #Nanotechnology #Microfluidics #PreciGenome #Nanogenerator #BiomedicalEngineering #PharmaceuticalScience #NanocarrierTechnology #PLGA

Advancements in Lipid Nanoparticle Utilization for Gene Editing Treatments. Lipid nanoparticles (LNPs) are emerging as a key non-viral vector for gene delivery, offering benefits such as transient expression, limited off-target events, in vivo administration, and scalability for large production. Since the COVID-19 pandemic, over 710 million doses of LNP-based mRNA vaccines have been administered globally, showcasing their feasibility and safety. Notably, NTLA-2001, an LNP-assisted CRISPR/Cas9 therapy for Transthyretin Amyloidosis, is currently in Phase III clinical trials. This demonstrates the potential of LNPs in advancing in vivo gene editing treatments. Stay tuned for more updates on the exciting progress in gene editing therapies! #GeneEditing #LipidNanoparticles #CRISPR #GeneTherapy #Biotechnology

The paper titled "Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR–Cas9 ribonucleoprotein" published in Nature Biotechnology presents a significant advancement in the field of gene editing, focusing on the delivery of CRISPR-Cas9 ribonucleoproteins (RNPs) via lipid nanoparticles (LNPs) to target specific organs like the liver and lungs. The study demonstrates the potential of this approach for therapeutic applications, particularly in treating genetic disorders affecting these organs. The authors also highlight the use of advanced instrumentation, such as the PreciGenome Nanogenerator flex-m synthesis instrument, to formulate the LNPs, ensuring precise control over particle size and composition. #lnp #drugdelivery #lipidnanoparticles #nanoparticles #drugdiscovery #mrna #formulation #cdmo #cro #pharmaceuticals #therapeutics

 Exciting Breakthrough in Lipid Nanoparticles for Gene Therapy A new study published in Nature Communications reveals a novel approach to encapsulate large-size DNA molecules using PEGylated lipid nanoparticles (LNPs). This innovative design improves immune system evasion and enhances gene delivery efficiency, addressing a major challenge in gene therapy.This research opens new doors for treating genetic disorders and advancing the potential of DNA-based therapies. A must-read for anyone in the fields of nanomedicine, drug delivery, or genetic engineering! #GeneTherapy #LipidNanoparticles #Nanomedicine #DrugDelivery #Biotechnology #DNAResearch #ImmunoEvasion #Bionanotechnology #HealthcareInnovation Read more here: https://lnkd.in/gvxdeCgf 

Lung and Liver Editing by Lipid Nanoparticle Delivery of a Stable CRISPR–Cas9 Ribonucleoprotein A recent study published in Nature Biotechnology by Nobel laureate Jennifer Doudna's group demonstrates a groundbreaking approach to genome editing in lung and liver tissues using lipid nanoparticles (LNPs) to deliver stable CRISPR–Cas9 ribonucleoproteins (RNPs). This innovative method holds significant promise for advancing gene therapy applications and treating genetic disorders. Key findings of the study include: Efficient Delivery: The LNPs facilitated the targeted delivery of CRISPR–Cas9 RNPs to lung and liver tissues, resulting in high levels of gene editing with minimal off-target effects. Stable RNPs: The encapsulation process preserved the stability and functionality of the CRISPR–Cas9 RNPs, which is crucial for achieving reliable and consistent gene editing outcomes. Therapeutic Potential: The ability to edit genes in lung and liver tissues opens new avenues for treating a range of genetic disorders, including cystic fibrosis and liver diseases. The research highlights the successful delivery of CRISPR–Cas9 RNPs to target tissues, achieving efficient and precise genome editing. The LNPs used in this study were synthesized using the #Nanogenerator Flex-m from #PreciGenome, a state-of-the-art instrument known for its high precision and reproducibility in nanoparticle synthesis. This technology enabled the researchers to encapsulate the #CRISPR–Cas9 RNPs effectively, ensuring their stability and activity during delivery. This research represents a significant step forward in the development of non-viral delivery systems for CRISPR-based therapies, offering a safer and more efficient alternative to traditional viral vectors. #LNP #lipidnanoparticle #geneedition #drugdelivery https://lnkd.in/eh6dpJPS